AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-20079423_ITM" title="Facts and information about INTAS PHARMA: ICICI SEEKS EXIT ROUTE (will sell its 12.5% stake in Intas Pharmaceutical as it is obliged to pay back its investors).">INTAS PHARMA: ICICI SEEKS EXIT ROUTE (will sell its 12.5% stake in Intas Pharmaceutical as it is obliged to pay back its investors).</a>
Close
Set up an RSS feed that alerts you when new articles from Asia Africa Intelligence Wire are available.
Frequently asked questions about RSS feeds
INTAS PHARMA: ICICI SEEKS EXIT ROUTE (will sell its 12.5% stake in Intas Pharmaceutical as it is obliged to pay back its investors).
(From India Business Insight)
ICICI Venture (IV) has decided to divest its 12.5 percent stake in Intas Pharma (IP), which it had acquired in 1996. The fund through which IV had financed the acquisition of stake in IP is coming to an end and IV is obliged to pay back its investors. IV, however, has decided not to go for an initial public offer.
...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- ChrysCap to buy 12 percent in Intas Pharma.(Company Profile)
- Newspaper article from: Economic Times (New Delhi, India) December 13, 2005 700+ words
...47 percent of its existing paid-up capital. The purchase is being done at the rate of a little over Rs 912 per share. Intas Pharma is a leading player in the high growth theurapeutic areas of neurology, psychiatry, cardiology, diabetology, gastroenterology...
- ChrysCap in race for ICICI Venture's stake in Intas.
- Newspaper article from: Economic Times (New Delhi, India) November 15, 2005 700+ words
...5 percent stake in Ahmedabad-based Intas Pharma, industry sources said. Intas, with...evinced an interest in the business. Intas Pharma's earnings per share have more than...business. Over the last few years, Intas Pharma's exports sales have grown more than...
- Costly cancer drugs face price control in India.
- Newspaper article from: Economic Times (New Delhi, India) January 6, 2005 700+ words
...marketed in India by companies like Dabur, Dr Reddy's, VHB Lifesciences, Sun Pharma, Cytomed (Alkem Lab's division), Intas Pharma and Biochem Pharmaceuticals. Although there are minor fluctuations in the price among the brands, a 300 mg vial would cost...
- Top 200 Pharma Company Profiles Available in One Source.
- Press release article from: M2 Presswire November 27, 2008 700+ words
...LTD - HETERO DRUGS - HIKAL LTD - HIRAN ORGOCHEM LTD - IND-SWIFT LABORATORIES LTD - INDOCO REMEDIES LTD - IND SWIFT LTD - INTAS PHARMA LTD - IPCA LABORATAORIES LTD - ISHITA DRUGS AND INDUSTRIES LTD - JK PHARMACHEM LTD - JAGSONPAL PHARMACEUTICAL LTD - JB CHEMICALS...
- Pharma cos in bad health, sales tumble 1.6% in May.
- Newspaper article from: Economic Times (New Delhi, India) June 23, 2005 700+ words
...Significantly, many of the smaller companies have improved their share in May compared with the same month last year. Intas Pharma, which ranks 20th in terms of MAT, topped the growth chart among the top 25 companies with an 11.8 percent growth, followed...
- INDIAN NEWSPAPER HIGHLIGHTS - JULY 15, 2005.
- News wire article from: AsiaPulse News July 15, 2005 700+ words
...investments. BUSINESS STANDARD: - The Aditya Birla group is in an advanced stage of negotiations with Ahmedabad-based Intas Pharma to take over the latter's biotechnology arm. With this acquisition, the Rs 28,000-crore Aditya Birla group will be...
- India: Phase III trials for biotech imports.
- Newspaper article from: Pharma Marketletter July 14, 2003 700+ words
...sold in the exporting country could be introduced into India with few or no extra trials. Ranbaxy, Cadila, Glenmar and Intas Pharma have been asked by the Genetic Engineering Approval Committee to undertake Phase III human trials in India on imported recombinant...
- ChrysCap sells 6.5% stake in MphasiS for Rs 130 cr.
- Newspaper article from: Economic Times (New Delhi, India) February 2, 2006 700+ words
...Its portfolio of investments includes Yes Bank, the Shriram group, IVRCL, Suzlon, Micro Inks, Balakrishna Tyres, and Intas Pharma. While ChrysCapital made a low key exit, the plans of major private equity player in MphasiS, Baring Private Equity Partners...